Oramed Pharmaceuticals Inc. · NASDAQ:ORMP
Oramed Pharmaceuticals — Investor Presentation (July 2008)
19 slides from Oramed Pharmaceuticals's investor presentation, Jul 23, 2008
Slide 1: Breakthrough Technology for a Brighter Future
Breakthrough Technology fora Brighter Future www.oramed.com
Slide 2: Safe Harbor
Safe Harbor Certain of the statements contained in this material are forward- looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from
Slide 3: Oramed Pharmaceuticals
Oramed Pharmaceuticals OTC Bulletin Board: ORMP Company with oral drug delivery platform World leading scientific team Experienced management team Diverse product pipeline Oral Insulin (ORMD 0801): Flag Ship Product
Slide 4: Oramed's Delivery Platform
Oramed’s Delivery Platform Normal digestion involves degradation of proteins/peptides Breakdown by acidic pH of stomach + digestive enzymes Oramed’s delivery technology ensures that the orally delivered peptides reach the absorption site intact and biologically active it enhances their absorption th
Slide 5: Diabetes
Diabetes Million people suffer from Diabetes in the US _ Insulinis a hormone that helps alone (ADA, 2007) move glucose from the bloodstream into the cells of the body. ‘46 Million Diabetics Worldwide (IDF, 2008)
Slide 6: Diabetes
Diabetes Type 1 (Juvenile) E Complete lack of insulin Insulin dependent, multiple injections required Type 2 (Adult Onset) Progressive insulin resistance associated with diabetes. Require oral medications and over time may require injections. Type 1O%
Slide 7: Diabetes — Type II
Diabetes — Type Il Progressive disease Initial treatment: life-style modification diet + exercise Oral medications Reduce resistance Stimulate insulin secretion Last stage: insulin Stages of Type 2 Diabetes: Criteria for advancing to next stage? AIC not at target: 57.0% 1005, ae MonoTherapy 5 7 i. —
Slide 8: The need for Oral Insulin
The need for Oral Insulin Oral insulin is the only Stages of Type 2 Dinhates: delivery system that mimics Griteria for advancing to next stage? bs Kintasical , AIC not at target: S 7.0% 1097. 5 i” . MonaTuerspy ; With an ore 2 Eg » J oats system, insulin can become 3 ‘er . a 8 Tet, an earlier treatm
Slide 9: History of Development
History of Development er 2009 Phase 2A April - Phase 1A Phase 1B July 2008 May - August 200 ‘jenuary= March 2008 | Successful pre- |i | e clinical results Phase 2 FDA April 2006 approved trials expected 3"¢ Swiss Cape FDA Consultant Quarter 2009 cone agreement —_| Encorium establishes October agree
Slide 10: Oral Insulin - Clinical Data
Oral Insulin - Clinical Data Elncrease in Insulin Levels Decline in Glucose Levels BE Decline in C-Peptide Levels C-Peptide 0 50 400 150 200 260 300 50 100 180 200 20 300
Slide 11: Road Map: Oral Insulin
Road Map: Oral Insulin TASK Tas | > ters < % 3.Phase 25 Trials 4.Validation prayed = Bi e/ tests new S.Swiss Caps Manufactur Tests 6 Analytical oe Years and Stability Tests 7-Toxicity Tox B.IND Filing
Slide 12: Oramed's Product Pipeline
Oramed’s Product Pipeline Oral Insulin Phase 2a trials completed July 2008 Rectal Insulin application Successful pre-clinical trials Starting phase 1 in South Africa Oral Flu Vaccine At pre-clinical phases
Slide 13: Competitive Landscape
Competitive Landscape Oral Insulin Capsule: Alternative Oral Insulin: Diabetology (UK, Phase 2) m Generex (Canada, Phase 3) — Emisphere Technologies Buccal delivery (US, Phase 2) B Biodel (US, Phase 3) — Biocon (India) Sublingual delivery Apollo Life Sciences mB MannkKind (US) -Inhaled (Australia, P
Slide 14: Financial Summary
Financial Summary E Market cap: $33 - $44 million E Cash on hand $5.1 million (as of July 15, 2008) Company expects to burn approx $1.2m per quarter, mostly R&D 56 Million Shares Outstanding Float 37 million — Major Shareholders B Nadav Kidron 18.4% B Zeev Bronfeld 10.9% B Hadassit 7.4% Leonard Sank
Slide 15: Management
Managemen Nadav Kidron, CEO Experience in a number of industries ranging from corporate law to technology startups. Founder of several technology start-ups. Chaime Orlev, CFO Many years of experience in financial management in publically traded companies. Specializes in the hi-tech sector and is a c
Slide 16: Scientific Advisory Board
ific Advisory Board Derek LeRoith, MD Professor of Medicine and Chief of Endocrinology, Diabetes and Bone Disease unit, Mount Sinai NY. Prof. Avram Herskho, MD, PhD Distinguished Professor in the Biochemistry unit in the B. Rappaport Facility of Medicine in the Technion in Haifa. Noble Prize Laureat
Slide 17: Summary - Oramed
Summary - Oramed Patented technology platform for oral delivery of medications Z " ay In the pipeline: wy r Oral and rectal delivery of Insulin Oral delivery of the flu-vaccine Strong management team, leading scientific team and clear proof of concept
Slide 18: Oramed in the News
Oramed in the News Oramed’s Oral Insulin Capsule listed as one of the five most promising drugs entering Phase 1 Trials by Thompson Pharma Chosen from hundreds of companies to represent Israel at the President’s Conference celebrating Israel’s 60" birthday ADA Poster Presentation San Francisco, June
Slide 19: Breakthrough Technology for a Brighter Future
Breakthrough Technology for a Brighter Future _ www.oramed.com
Oramed Pharmaceuticals — Investor Presentation (July 2008) on 6ix